Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Pfizer Inc. (PFE : NYSE)
 
 • Company Description   
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.

Number of Employees: 81,000

 
 • Price / Volume Information   
Yesterday's Closing Price: $22.28 Daily Weekly Monthly
20 Day Moving Average: 46,843,724 shares
Shares Outstanding: 5,685.37 (millions)
Market Capitalization: $126,669.95 (millions)
Beta: 0.58
52 Week High: $31.54
52 Week Low: $20.92
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 1.69% -3.64%
12 Week -12.73% -5.72%
Year To Date -16.02% -12.73%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
66 HUDSON BOULEVARD EAST
-
NEW YORK,NY 10001
USA
ph: 212-733-2323
fax: 302-655-5049
ir@pfizer.com http://www.pfizer.com
 
 • General Corporate Information   
Officers
Albert Bourla - Chief Executive Officer; Chairman and Director
David M. Denton - Chief Financial Officer and Executive Vice Preside
Jennifer B. Damico - Senior Vice President and Controller
Ronald E. Blaylock - Director
Mortimer J. Buckley - Director

Peer Information
Pfizer Inc. (AGN.)
Pfizer Inc. (NVS)
Pfizer Inc. (NVO)
Pfizer Inc. (LLY)
Pfizer Inc. (RHHBY)
Pfizer Inc. (JNJ)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: Large Cap Pharma
Sector: Medical
CUSIP: 717081103
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 07/29/25
Share - Related Items
Shares Outstanding: 5,685.37
Most Recent Split Date: 7.00 (3.00:1)
Beta: 0.58
Market Capitalization: $126,669.95 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 7.72%
Current Fiscal Quarter EPS Consensus Estimate: $0.58 Indicated Annual Dividend: $1.72
Current Fiscal Year EPS Consensus Estimate: $3.07 Payout Ratio: 0.54
Number of Estimates in the Fiscal Year Consensus: 9.00 Change In Payout Ratio: 0.00
Estmated Long-Term EPS Growth Rate: 9.00% Last Dividend Paid: 05/09/2025 - $0.43
Next EPS Report Date: 07/29/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 7.26
Trailing 12 Months: 6.94
PEG Ratio: 0.81
Price Ratios
Price/Book: 1.39
Price/Cash Flow: 5.11
Price / Sales: 2.03
EPS Growth
vs. Year Ago Period: 12.20%
vs. Previous Quarter: 46.03%
Sales Growth
vs. Year Ago Period: -7.82%
vs. Previous Quarter: -22.79%
ROE
03/31/25 - 20.33
12/31/24 - 19.60
09/30/24 - 16.28
ROA
03/31/25 - 8.53
12/31/24 - 8.15
09/30/24 - 6.68
Current Ratio
03/31/25 - 1.26
12/31/24 - 1.17
09/30/24 - 1.00
Quick Ratio
03/31/25 - 0.96
12/31/24 - 0.92
09/30/24 - 0.73
Operating Margin
03/31/25 - 29.26
12/31/24 - 27.85
09/30/24 - 24.53
Net Margin
03/31/25 - 12.62
12/31/24 - 12.62
09/30/24 - 7.07
Pre-Tax Margin
03/31/25 - 11.83
12/31/24 - 12.61
09/30/24 - 6.49
Book Value
03/31/25 - 15.98
12/31/24 - 15.62
09/30/24 - 16.33
Inventory Turnover
03/31/25 - 1.54
12/31/24 - 1.59
09/30/24 - 1.76
Debt-to-Equity
03/31/25 - 0.64
12/31/24 - 0.65
09/30/24 - 0.63
Debt-to-Capital
03/31/25 - 38.87
12/31/24 - 39.35
09/30/24 - 38.52
 

Powered by Zacks Investment Research ©